Adapter molecule crk Antibodies

Adapter molecule crk (CRK)

Isoform Crk-II: Regulates cell adhesion, spreading and migration. Mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner.

Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4. May regulate the EFNA5-EPHA3 signaling.

Gene Information

Human
Gene Name:	CRK
Uniprot:	P46108
Entrez:	1398

Family

Belongs to:
CRK family

Alternative Names

adapter molecule crk; avian sarcoma virus CT10 (v-crk) oncogene homolog; Crk; CRKII; p38; Proto-oncogene c-Crk; v-crk avian sarcoma virus CT10 oncogene homolog; v-crk sarcoma virus CT10 oncogene homolog (avian)

Molecular Weight

Mass (kDA):
33.831 kDA

Genomic Context

Human
Location:	17p13.3
Sequence:	17; NC_000017.11 (1420693..1456232, complement)

Subcellular Localizations

Cytoplasm. Cell membrane. Translocated to the plasma membrane upon cell adhesion.

Diseases

• Tissue Adhesions
• Malignant Neoplasms
• Neoplasms
• Cell Transformation, Neoplastic
• Cell Invasion
• Leukemia
• Neoplasm Metastasis
• Myeloid Leukemia
• Myeloid Leukemia, Chronic
• Sarcoma
• Neoplasm Invasiveness
• Malignant Paraganglionic Neoplasm
• Carcinoma

• Metaplastic Cell Transformation
• Malignant Neoplasm Of Breast
• Mammary Neoplasms
• Sarcoma, Avian
• Carcinogenesis
• Lung Neoplasms
• Malignant Neoplasm Of Lung

Pathways

• Cell Migration
• Cell Adhesion
• Cell Motility
• Cell Cycle
• Localization
• Cell Proliferation
• Cell Growth
• Rna Interference
• Phagocytosis
• Cell Death
• Pathogenesis
• T Cell Activation
• Endocytosis

• Cell Activation
• Cytokinesis
• Hyperphosphorylation
• Wound Healing
• Transport
• Cell Division
• Angiogenesis

PTMs

• Phosphorylation
• Dephosphorylation
• Cleavage
• Ribosylation
• Methylation
• Myristoylation

• Biotinylation
• Ubiquitination
• Reduction
• Farnesylation
• Acetylation
• Palmitoylation

Research Areas

• Apoptosis
• Ovarian Carcinoma Cell Markers

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CRK

Best Uses Of The CRK Marker From Boster Bio

This article will cover the clinical applications of the monoclonal Anti-Crk2 anti-mouse antibody. We will also talk about Steven Boster's work and background. We will also discuss his history, as well as his work and what makes him a great scientist. Continue reading to find out more. Don't miss his bio! It's worth the read!

Monoclonal Anti-Crk2 antibody

The Anti-Crk2 monoclone antibody from Boster Bio is designed to react with Human and is stored at -20 degrees C for up to a year. Boster Bio's antibodies have been tested against positive and negative samples. They can be used on many platforms, including ELISA. The antibody is available in a wide range of concentrations to suit your needs.

Boster Bio's anti-Crk2 monoclonal targets the receptor for this protein. This receptor plays a critical role in cell signaling. This product is highly effective against various types of cancer cells, including human tumors. The antibody is made in a laboratory by Boster Bio. The safety and efficacy of the antibody for many patients with cancer has been confirmed by the research team.

Boster Bio created this antibody to recognize human Crk2 as well as guanin. This protein's CDRwo refers to the Chinese character CDRwo. This antibody is able to cross-link and detect these proteins in a wide variety of cancer samples. Anti-Crk2 has the potential to cause allergic reactions, but it is an extremely useful immunoabsorbent.

This antibody also binds to a variety of other targets, including TDP-43piroteinoacchino, a type of protein in the body. It also recognizes a wide range of other targets, including TDP-43piroteinopachino, which is found in human fibroblasts. This antibody is able to reduce tumor growth and promote cell signaling in cancer tissues.

Clinical applications

C-reactive protein (CRP) is a sensitive acute-phase protein that reflects inflammation and tissue injury. It is cheap and easy to access. CRP can be used in clinical settings for diagnostic support, screening studies, and serial measurement of therapeutic response. Elevated levels of CRP may affect several types of patients. Continue reading to find out more about this marker. This article will describe the basic characteristics of the CRK marker and describe how it may be used.

This marker was first described in 1990. It was discovered that it is associated with a series genetic events involving key regulatory gene genes that confer an advantage on the clonal population cancer cells. Molecular detection methods based on gene mutation determination have been developed for several years, although their clinical utility is limited. However, these new markers may prove to be useful in predicting clinical outcomes and subclassification of tumors.

The study also identified CTC gene marker markers for diagnosis and prognosis. There were also ten studies looking at exosomes as a marker. These gene marker have similar molecular roles, including protein binding as well as the regulation of cell assembly and movement. The findings of the systematic review are helpful in developing molecular diagnostic tools. The CRK gene marker may be useful in the diagnosis or prognosis for CRC.

CTC counts can predict the risk of relapse in adjuvant chemotherapy patients. CTC detection could be useful in the selection of patients at high-risk stages II CRC who are eligible for adjuvant treatment. However, interventional studies are required to evaluate the benefits of chemotherapy for these patients. In the meantime, the clinical use of the CRK marker has been approved. This marker has a bright future. It is an important tool in the diagnosis and prognosis for colorectal carcinoma.

The CRK marker is useful for identifying potential therapeutic targets. It also allows monitoring the effectiveness and efficiency of cancer therapies. The CRK markers may be used to detect tumor resistance mechanisms, allowing patients to receive the best possible treatment. It may also be used to identify patients who respond to therapy and those who do not. The CRK marker might be included in tumor-specific blood testing and can help clinicians personalize therapy for patients.

Five genes have been identified as having biologic significance by the CxBladder gene expression study. CxBladder has created three tests that can help doctors identify high-risk individuals using these genes. These tests are called Triage (Monitor) and Detect (Detect). These tests can help guide treatment and allow for early detection of CRC. These tests cannot replace surgery or chemotherapy. They can improve local tumor control.

History of Steven Boster

Steve Boster passed away on June 26, 2022. He was a native of Joliet, IL. He was a long-standing manager of retail sales. He also served in the U.S. Army and was a member of Concordia Hall in Staunton. His 2 daughters, Natosha Peck, and Crystal Boster are his surviving children, as well his six grandchildren. He is also survived his four brothers, Jack Boster Sandra Blanton and Lisa Milton as well numerous nieces and nephews.

Steve was a family-oriented man. He was devoted to his family. His passions included singing loud in front of his loved ones and being a huge sports fan. He was always the one to help when his vehicle broke down at three in the morning. He enjoyed auto racing, and showed up to appointments even in the coldest weather. He also treated his friends as family. People who knew Steve will always remember his generosity, his willingness to help others.